$XGN
Exagen Inc Stock $xgn

$xgn Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000127473721000015 Filed on March 16, 2021

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$10.21M	$40.39M	$9.640M
YoY Change	5.91%	24.5%
Cost Of Revenue	$4.590M	$18.81M	$4.000M
YoY Change	14.75%	22.3%
Gross Profit	$5.620M	$21.58M	$5.640M
YoY Change	-0.35%	26.48%
Gross Profit Margin	55.04%	53.43%	58.51%
Selling, General & Admin	$7.920M	$28.70M	$5.260M
YoY Change	50.57%	45.88%
% of Gross Profit	140.93%	133.01%	93.26%
Research & Development	$570.0K	$2.176M	$530.0K
YoY Change	7.55%	2.4%
% of Gross Profit	10.14%	10.08%	9.4%
Depreciation & Amortization	$110.0K	$600.0K	$150.0K
YoY Change	-26.67%	0.0%
% of Gross Profit	1.96%	2.78%	2.66%
Operating Expenses	$8.480M	$30.88M	$5.790M
YoY Change	46.46%	41.64%
Operating Profit	-$2.860M	-$9.299M	-$150.0K
YoY Change	1806.67%	90.55%
Interest Expense	-$770.0K	$3.491M	-$1.140M
YoY Change	-32.46%	21.72%
% of Operating Profit
Other Income/Expense, Net	$250.0K	$510.0K	$40.00K
YoY Change	525.0%	355.36%
Pretax Income	-$3.380M	-$12.01M	-$1.260M
YoY Change	168.25%	51.07%
Income Tax	$30.00K	$25.00K
% Of Pretax Income
Net Earnings	-$3.410M	-$12.04M	-$1.320M
YoY Change	158.33%	50.25%
Net Earnings / Revenue	-33.4%	-29.81%	-13.69%
Basic Earnings Per Share
Diluted Earnings Per Share	-$952.5K	-$3.363M	-$112.7K
COMMON SHARES
Basic Shares Outstanding	12.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$72.10M	$72.08M
YoY Change		447.72%
Cash & Equivalents	$72.08M	$72.08M	$13.16M
Short-Term Investments
Other Short-Term Assets	$1.427M	$3.450M	$1.174M
YoY Change	21.55%	56.82%
Inventory
Prepaid Expenses
Receivables	$5.715M	$5.720M	$5.952M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$81.25M	$81.25M	$21.31M
YoY Change	281.24%	281.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.380M	$1.380M	$1.566M
YoY Change	-11.88%	-12.1%
Goodwill	$5.506M		$5.506M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$174.0K	$170.0K	$503.0K
YoY Change	-65.41%	-66.0%
Total Long-Term Assets	$7.060M	$7.060M	$7.575M
YoY Change	-6.8%	-6.86%
TOTAL ASSETS
Total Short-Term Assets	$81.25M	$81.25M	$21.31M
Total Long-Term Assets	$7.060M	$7.060M	$7.575M
Total Assets	$88.31M	$88.31M	$28.89M
YoY Change	205.71%	205.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.476M	$1.480M	$1.279M
YoY Change	15.4%	15.63%
Accrued Expenses	$4.419M	$4.420M	$3.923M
YoY Change	12.64%	12.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.895M	$5.900M	$8.952M
YoY Change	-34.15%	-34.08%
LONG-TERM LIABILITIES
Long-Term Debt	$25.85M	$25.85M	$24.62M
YoY Change	5.02%	5.0%
Other Long-Term Liabilities	$638.0K	$640.0K	$304.0K
YoY Change	109.87%	-64.64%
Total Long-Term Liabilities	$26.49M	$26.49M	$24.92M
YoY Change	6.3%	0.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.895M	$5.900M	$8.952M
Total Long-Term Liabilities	$26.49M	$26.49M	$24.92M
Total Liabilities	$32.65M	$32.65M	$35.62M
YoY Change	-8.34%	-8.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.6M		-$152.6M
YoY Change	7.89%
Common Stock	$13.00K		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$55.66M	$55.66M	-$112.0M
YoY Change
Total Liabilities & Shareholders Equity	$88.31M	$88.31M	$28.89M
YoY Change	205.71%	205.68%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$3.410M	-$12.04M	-$1.320M
YoY Change	158.33%	50.25%
Depreciation, Depletion And Amortization	$110.0K	$600.0K	$150.0K
YoY Change	-26.67%	0.0%
Cash From Operating Activities	-$3.930M	-$9.711M	-$1.870M
YoY Change	110.16%	4.41%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$403.0K	-$70.00K
YoY Change	-71.43%	102.51%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$300.0K	$1.000M
YoY Change	-100.0%
Cash From Investing Activities	-$20.00K	-$103.0K	$930.0K
YoY Change	-102.15%	-48.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.800M	$68.73M	8.720M
YoY Change	-120.64%	501.72%
NET CHANGE
Cash From Operating Activities	-3.930M	-$9.711M	-1.870M
Cash From Investing Activities	-20.00K	-$103.0K	930.0K
Cash From Financing Activities	-1.800M	$68.73M	8.720M
Net Change In Cash	-5.750M	$58.92M	7.780M
YoY Change	-173.91%	2963.96%
FREE CASH FLOW
Cash From Operating Activities	-$3.930M	-$9.711M	-$1.870M
Capital Expenditures	-$20.00K	$403.0K	-$70.00K
Free Cash Flow	-$3.910M	-$10.11M	-$1.800M
YoY Change	117.22%	6.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001274737
CY2019Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0054456
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-39049
CY2020	dei	Entity Registrant Name EntityRegistrantName	EXAGEN INC.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0434866
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	1261 Liberty Way
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Vista
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92081
CY2020	dei	City Area Code CityAreaCode	(760)
CY2020	dei	Local Phone Number LocalPhoneNumber	560-1501
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	XGN
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	83400000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12669816	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57448000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72084000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8910000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5715000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	4159000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	3451000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	70517000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	81250000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2102000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1380000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	5506000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	5506000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	250000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	174000	USD
CY2020Q4	us-gaap	Assets Assets	78375000	USD
CY2019Q4	us-gaap	Assets Assets	88310000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3014000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1476000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5757000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4419000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8771000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5895000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26659000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	25854000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	158000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	264000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	948000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	638000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	36536000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	32651000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12652308	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12652308	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12560990	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12560990	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	223115000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220248000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181289000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164602000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	41839000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	55659000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78375000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88310000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41975000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40387000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16559000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18808000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37033000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28702000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3568000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2176000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	57160000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	49686000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-15185000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-9299000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2565000	USD
CY2019	us-gaap	Interest Expense InterestExpense	3491000	USD
CY2020	exdx	Increase Decrease In Fair Value Of Financial Instruments IncreaseDecreaseInFairValueOfFinancialInstruments	0	USD
CY2019	exdx	Increase Decrease In Fair Value Of Financial Instruments IncreaseDecreaseInFairValueOfFinancialInstruments	267000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	984000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	510000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-16766000	USD
CY2019	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-12013000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-79000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16687000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-12038000	USD
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2019	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4640000	USD
CY2020	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2019	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	13601000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-16687000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30279000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.46
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12632780	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3578771	shares
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	532606084	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	105232000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-111966000	USD
CY2019	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4640000	USD
CY2019	exdx	Adjustments To Additional Paid In Capital Temporary Equity Accretion To Redemption Value AdjustmentsToAdditionalPaidInCapitalTemporaryEquityAccretionToRedemptionValue	4640000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	572000	USD
CY2019	exdx	Adjustments To Additional Paid In Capital Issuance Of Temporary Equity AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity	6741000	USD
CY2019	exdx	Temporary Equity Deemed Dividends With Beneficial Conversion Feature TemporaryEquityDeemedDividendsWithBeneficialConversionFeature	6741000	USD
CY2019	exdx	Adjustments To Additional Paid In Capital Temporary Equity With Beneficial Conversion Feature AdjustmentsToAdditionalPaidInCapitalTemporaryEquityWithBeneficialConversionFeature	6741000	USD
CY2019	exdx	Temporary Equity Deemed Dividend Shares Issued TemporaryEquityDeemedDividendSharesIssued	97592739	shares
CY2019	exdx	Temporary Equity Deemed Dividend TemporaryEquityDeemedDividend	6860000	USD
CY2019	exdx	Adjustments To Additional Paid In Capital Temporary Equity Deemed Dividends AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDeemedDividends	6860000	USD
CY2019	exdx	Temporary Equity Shares Redeemed Upon Conversion TemporaryEquitySharesRedeemedUponConversion	1012573679	shares
CY2019	exdx	Temporary Equity Shares Redeemed Upon Conversion Amount TemporaryEquitySharesRedeemedUponConversionAmount	138906000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	138906000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50444000	USD
CY2019	exdx	Stock Issued During Period Value Warrants Exercised Net StockIssuedDuringPeriodValueWarrantsExercisedNet	511000	USD
CY2019	exdx	Adjustments To Additional Paid In Capital Reclassification Of Preferred Stock Warrant Liability AdjustmentsToAdditionalPaidInCapitalReclassificationOfPreferredStockWarrantLiability	726000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-12038000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	55659000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	142000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2694000	USD
CY2020	exdx	Stock Issued During Period Value Warrants Exercised Net StockIssuedDuringPeriodValueWarrantsExercisedNet	18000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16687000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	41839000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-16687000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-12038000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	546000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	591000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	274000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	691000	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	531000	USD
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	546000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-267000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-106000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-20000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2694000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	572000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3195000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-237000	USD
CY2020	exdx	Increase Decrease In Prepaid Expense And Current Other Assets IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets	708000	USD
CY2019	exdx	Increase Decrease In Prepaid Expense And Current Other Assets IncreaseDecreaseInPrepaidExpenseAndCurrentOtherAssets	1255000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	15000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	24000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	986000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	528000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1596000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	688000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14084000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9711000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	455000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	403000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	300000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-455000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-103000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	142000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	18000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	249000	USD
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	138000	USD
CY2020	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan	2865000	USD
CY2019	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan	0	USD
CY2020	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Repayments Of Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan	2865000	USD
CY2019	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Repayments Of Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActRepaymentsOfLoan	0	USD
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	50444000	USD
CY2020	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	21000	USD
CY2019	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-97000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	68734000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14636000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58920000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72184000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13264000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57548000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72184000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1758000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	2288000	USD
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2019	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4640000	USD
CY2020	exdx	Equipment Purchased Under Capital Lease EquipmentPurchasedUnderCapitalLease	260000	USD
CY2019	exdx	Equipment Purchased Under Capital Lease EquipmentPurchasedUnderCapitalLease	654000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	553000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	138906000	USD
CY2020	exdx	Noncash Exercise Of Stock Purchase Warrants NoncashExerciseOfStockPurchaseWarrants	0	USD
CY2019	exdx	Noncash Exercise Of Stock Purchase Warrants NoncashExerciseOfStockPurchaseWarrants	511000	USD
CY2020	exdx	Deferred Offering Costs Included Within Current Liabilities DeferredOfferingCostsIncludedWithinCurrentLiabilities	40000	USD
CY2019	exdx	Deferred Offering Costs Included Within Current Liabilities DeferredOfferingCostsIncludedWithinCurrentLiabilities	0	USD
CY2020	exdx	Reclassification Of Temporary Equity And Liabilities To Permanent Equity ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity	0	USD
CY2019	exdx	Reclassification Of Temporary Equity And Liabilities To Permanent Equity ReclassificationOfTemporaryEquityAndLiabilitiesToPermanentEquity	726000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181300000	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risk and Uncertainties</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, and accounts receivable. Substantially all the Company's cash and cash equivalents are held at one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits.</span></div>
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57448000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41975000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40387000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72084000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	100000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	100000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57548000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72184000	USD
CY2020	us-gaap	Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment	Collection of the Company's net revenues from payors is normally a function of providing complete and correct billing information to the healthcare insurers and generally occurs within 30 to 90 days of billing
CY2020Q4	exdx	Joint Venture Quarterly Promotion Fee Capped Amount Percentage Above Baseline JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline	0.05
CY2020Q3	exdx	Joint Venture Quarterly Promotion Fee Capped Amount Percentage Above Baseline JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline	0.05
CY2020Q4	exdx	Joint Venture Quarterly Prescribed Units JointVentureQuarterlyPrescribedUnits	28750	unit
CY2020Q4	exdx	Joint Venture Quarterly Promotion Fee JointVentureQuarterlyPromotionFee	300000	USD
CY2020Q4	exdx	Joint Venture Quarterly Promotion Fee Capped Amount Percentage Above Baseline JointVentureQuarterlyPromotionFeeCappedAmountPercentageAboveBaseline	0.05
CY2020	us-gaap	Advertising Expense AdvertisingExpense	1300000	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1600000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2414228	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1836815	shares
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1203000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1427000	USD
CY2020Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	68000	USD
CY2019Q4	exdx	Prepaid Maintenance And Insurance Contracts PrepaidMaintenanceAndInsuranceContracts	1768000	USD
CY2020Q4	exdx	Prepaid Maintenance And Insurance Contracts PrepaidMaintenanceAndInsuranceContracts	2229000	USD
CY2019Q4	us-gaap	Prepaid Royalties PrepaidRoyalties	123000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	659000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	133000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4159000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3451000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5043000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3775000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2941000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2395000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2102000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1380000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	600000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3589000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2362000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	147000	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	145000	USD
CY2020Q4	exdx	Accrued Purchase Goods And Services Current AccruedPurchaseGoodsAndServicesCurrent	311000	USD
CY2019Q4	exdx	Accrued Purchase Goods And Services Current AccruedPurchaseGoodsAndServicesCurrent	319000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	221000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	727000	USD
CY2020Q4	exdx	Accrued Liabilities Clinical Study Current AccruedLiabilitiesClinicalStudyCurrent	228000	USD
CY2019Q4	exdx	Accrued Liabilities Clinical Study Current AccruedLiabilitiesClinicalStudyCurrent	40000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	308000	USD
CY2019Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	238000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	953000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4419000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	588000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5757000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1755000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2996000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	15619000	USD
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	14280000	USD
CY2020Q4	exdx	Long Term Debt Including Undiscounted Interest LongTermDebtIncludingUndiscountedInterest	34650000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	296000	USD
CY2020Q4	exdx	Long Term Debt Undiscounted Interest Amount LongTermDebtUndiscountedInterestAmount	7695000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	26659000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	344000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	590000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	318000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	613000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	231000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	626000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	58000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	640000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	32120	shares
CY2020Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	6000000.0	USD
CY2020Q4	exdx	Purchase Obligation Annual Increase In Commitment Percentage PurchaseObligationAnnualIncreaseInCommitmentPercentage	0.15
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	654000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	55000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	951000	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3178000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	67000	USD
CY2020Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	884000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	308000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	576000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2020Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	4100000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	13.20
CY2019Q3	exdx	Temporary Equity Deemed Dividend TemporaryEquityDeemedDividend	6900000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	426827	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1375542	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.33
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M28D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23654000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	951031	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.02
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	47549	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.27
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	293412	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.46
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	9851	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	29.02
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1975761	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	25.40
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1000000.0	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.81
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6750000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1975761	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	11.81
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	6750000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	464606	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.75
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y3D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3362000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.79
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1000000.0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2694000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	572000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8500000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3775872	shares
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	27000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-117000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	10000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-106000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-79000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036
CY2020	exdx	Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent	0
CY2019	exdx	Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockLiabilitiesPercent	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.226
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.361
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.598
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.018
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.016
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17733000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15287000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	629000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	419000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	1448000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	590000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1306000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	744000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	117000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	225000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21233000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	795000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16797000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17265000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20596000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16797000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	637000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	468000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	336000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	336000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	459000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	396000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	732000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	158000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	264000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21138000	USD
CY2020	exdx	Valuation Allowance Deferred Tax Asset Decrease Recorded As A Benefit To Income Tax Provision Amount ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount	0	USD
CY2019	exdx	Valuation Allowance Deferred Tax Asset Decrease Recorded As A Benefit To Income Tax Provision Amount ValuationAllowanceDeferredTaxAssetDecreaseRecordedAsABenefitToIncomeTaxProvisionAmount	4341000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3799000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20596000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16797000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	70600000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	60700000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	48900000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	43500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	43500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	27100000	USD
CY2020Q4	exdx	Operating Loss Carryforwards Not Utilized OperatingLossCarryforwardsNotUtilized	61800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000	USD
CY2020Q1	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Deferred Tax Assets Valuation Allowance CoronavirusAidReliefAndEconomicSecuritiesCARESActDeferredTaxAssetsValuationAllowance	100000	USD
CY2020Q2	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan	700000	USD
CY2020	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Other Non Operating Income Expense CoronavirusAidReliefAndEconomicSecuritiesCARESActOtherNonOperatingIncomeExpense	700000	USD
CY2020Q2	exdx	Coronavirus Aid Relief And Economic Securities Cares Act Proceeds From Loan CoronavirusAidReliefAndEconomicSecuritiesCARESActProceedsFromLoan	2900000	USD

Files In Submission

Name	View Source	Status
0001274737-21-000015-index-headers.html	Edgar Link	pending
0001274737-21-000015-index.html	Edgar Link	pending
0001274737-21-000015.txt	Edgar Link	pending
0001274737-21-000015-xbrl.zip	Edgar Link	pending
ex1025-amend3tocoxpromotio.htm	Edgar Link	pending
ex1034-amend1to1221liberty.htm	Edgar Link	pending
ex1046-executivecicseveran.htm	Edgar Link	pending
ex105-formofrsuagreement20.htm	Edgar Link	pending
ex231-2020bdoconsent.htm	Edgar Link	pending
exdx-20201231.htm	Edgar Link	pending
exdx-20201231.xsd	Edgar Link	pending
exdx-20201231_cal.xml	Edgar Link	unprocessable
exdx-20201231_def.xml	Edgar Link	unprocessable
exdx-20201231_g1.jpg	Edgar Link	pending
exdx-20201231_g2.jpg	Edgar Link	pending
exdx-20201231_g3.jpg	Edgar Link	pending
exdx-20201231_g4.jpg	Edgar Link	pending
exdx-20201231_htm.xml	Edgar Link	completed
exdx-20201231_lab.xml	Edgar Link	unprocessable
exdx-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xgn311-123120.htm	Edgar Link	pending
xgn312-123120.htm	Edgar Link	pending
xgn321-123120.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XGN
Exagen Inc Stock $xgn

2019 Q4 Form 10-K Financial Statement

#000127473721000015 Filed on March 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XGN Exagen Inc Stock $xgn

2019 Q4 Form 10-K Financial Statement

#000127473721000015 Filed on March 16, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XGN
Exagen Inc Stock $xgn